Literature DB >> 31811428

Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?

Willie Magnus Luedemann1, Dominik Geisel1, Bernhard Gebauer1, Dirk Schnapauff1, Julius Chapiro2, Gero Wieners1, Ingo Steffen1, Johannes Kahn3.   

Abstract

OBJECTIVES: In this study, pre-treatment target lesion vascularisation in either contrast-enhanced (CE) CT or MRI and post-treatment lipiodol deposition in native CT scans were compared in HCC patients who underwent their first cTACE treatment. We analysed the impact of stratification according to cTACE selectivity on these correlations.
METHODS: Seventy-eight HCC patients who underwent their first cTACE procedure were retrospectively included. Pre-treatment tumour vascularisation in arterial contrast phase and post-treatment lipiodol deposition in native CT scans were evaluated using the qEASL (quantitative tumour enhancement) method. Correlations were analysed using scatter plots, the Pearson correlation coefficient (PCC) and linear regression analysis. Subgroup analysis was performed according to lobar, segmental and subsegmental execution of cTACE.
RESULTS: Arterial tumour volumes in both baseline CE CT (R2 = 0.83) and CE MR (R2 = 0.82) highly correlated with lipiodol deposition after cTACE. The regression coefficient between lipiodol deposition and enhancing tumour volume was 1.39 for CT and 0.33 for MR respectively, resulting in a ratio of 4.24. After stratification according to selectivity of cTACE, the regression coefficient was 0.94 (R2 = 1) for lobar execution, 1.38 (R2 = 0.96) for segmental execution and 1.88 (R2 = 0.89) for subsegmental execution in the CE CT group.
CONCLUSIONS: Volumetric lipiodol deposition can be used as a reference to compare different imaging modalities in detecting vital tumour volumes. That approach proved CE MRI to be more sensitive than CE CT. Selectivity of cTACE significantly impacts the respective regression coefficients which allows for an innovative approach to the assessment of technical success after cTACE with a multitude of possible applications. KEY POINTS: • Lipiodol deposition after cTACE highly correlates with pre-treatment tumour vascularisation and can be used as a reference to compare different imaging modalities in detecting vital tumour volumes. • Lipiodol deposition also correlates with the selectivity of cTACE and can therefore be used to quantify the technical success of the intervention.

Entities:  

Keywords:  Carcinoma; Chemoembolisation; Hepatocellular; Therapeutic; Treatment outcome

Mesh:

Substances:

Year:  2019        PMID: 31811428     DOI: 10.1007/s00330-019-06430-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  24 in total

1.  [Comparison of contrast resolution between dynamic MRI and dynamic CT in liver scanning].

Authors:  Akio Ogura; Akira Miyai; Fumie Maeda; Takaharu Hongoh; Rikiya Kikumoto
Journal:  Nihon Hoshasen Gijutsu Gakkai Zasshi       Date:  2002-02

Review 2.  Intraarterial therapies for primary liver cancer: state of the art.

Authors:  Julius Chapiro; Vania Tacher; Jean-François Geschwind
Journal:  Expert Rev Anticancer Ther       Date:  2013-10-07       Impact factor: 4.512

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

4.  Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization.

Authors:  Beom Kyung Kim; Seung Up Kim; Myeong-Jin Kim; Kyung Ah Kim; Do Young Kim; Jun Yong Park; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon
Journal:  Clin Cancer Res       Date:  2012-12-07       Impact factor: 12.531

5.  Hepatocellular carcinoma: have we finally found the ultimate staging system for HCC?

Authors:  Julius Chapiro; Jean-François Geschwind
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-05-06       Impact factor: 46.802

6.  Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.

Authors:  Vania Tacher; MingDe Lin; Rafael Duran; Hooman Yarmohammadi; Howard Lee; Julius Chapiro; Michael Chao; Zhijun Wang; Constantine Frangakis; Jae Ho Sohn; Mitchell Gil Maltenfort; Timothy Pawlik; Jean-François Geschwind
Journal:  Radiology       Date:  2015-07-01       Impact factor: 11.105

Review 7.  Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.

Authors:  Julius Chapiro; MingDe Lin; Rafael Duran; Rüdiger E Schernthaner; Jean-François Geschwind
Journal:  Expert Rev Anticancer Ther       Date:  2014-11-05       Impact factor: 4.512

8.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

9.  Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization.

Authors:  MingDe Lin; Olivier Pellerin; Nikhil Bhagat; Pramod P Rao; Romaric Loffroy; Roberto Ardon; Benoit Mory; Diane K Reyes; Jean-François Geschwind
Journal:  J Vasc Interv Radiol       Date:  2012-12       Impact factor: 3.464

10.  Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging.

Authors:  Jie Peng; Shuai Kang; Zhengyuan Ning; Hangxia Deng; Jingxian Shen; Yikai Xu; Jing Zhang; Wei Zhao; Xinling Li; Wuxing Gong; Jinhua Huang; Li Liu
Journal:  Eur Radiol       Date:  2019-07-22       Impact factor: 5.315

View more
  4 in total

1.  Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.

Authors:  Tabea Borde; Nariman Nezami; Fabian Laage Gaupp; Lynn Jeanette Savic; Tamar Taddei; Ariel Jaffe; Mario Strazzabosco; MingDe Lin; Rafael Duran; Christos Georgiades; Kelvin Hong; Julius Chapiro
Journal:  Radiology       Date:  2022-04-12       Impact factor: 29.146

2.  Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Tian-Cheng Wang; Tian-Zhi An; Jun-Xiang Li; Zi-Shu Zhang; Yu-Dong Xiao
Journal:  Front Mol Biosci       Date:  2021-03-18

3.  The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer.

Authors:  Yunpeng Kong; Yan Jing; Hongmei Sun; Shisheng Zhou
Journal:  J Healthc Eng       Date:  2022-02-21       Impact factor: 2.682

4.  Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE.

Authors:  Jun-Xiang Li; Peng-Fei Pang; Tian-Cheng Wang; Tian-Zhi An
Journal:  Risk Manag Healthc Policy       Date:  2021-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.